These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27912175)

  • 21. Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
    Zhai Z; Li R; Bai X; Ning X; Lin Z; Zhao X; Jin Y; Yin Y
    Bioorg Med Chem; 2019 Sep; 27(18):4124-4142. PubMed ID: 31395509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
    Kawahata W; Asami T; Irie T; Sawa M
    Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.
    Turetsky A; Kim E; Kohler RH; Miller MA; Weissleder R
    Sci Rep; 2014 Apr; 4():4782. PubMed ID: 24759210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
    Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Dou D; Sha W; Diao Y; Su R; Qiao Y; Yu Z; Zhao Z; Li H; Chen Z; Xu Y
    Bioorg Chem; 2022 Feb; 119():105541. PubMed ID: 34910982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
    Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
    Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
    Ren J; Shi W; Zhao D; Wang Q; Chang X; He X; Wang X; Gao Y; Lu P; Zhang X; Xu H; Zhang Y
    Bioorg Med Chem; 2020 Jan; 28(2):115236. PubMed ID: 31843459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
    Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.
    Ran F; Liu Y; Zhu J; Deng X; Wu H; Tao W; Xie X; Hu Y; Zhang Y; Ling Y
    Bioorg Chem; 2023 May; 134():106479. PubMed ID: 36989958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
    Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A
    J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
    Tang G; Liu L; Wang X; Pan Z
    Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
    Li R; Du Y; Shen J
    SAR QSAR Environ Res; 2018 Nov; 29(11):847-873. PubMed ID: 30280589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation.
    Xiao M; Zhu M; Wu S; Ma L; Qi L; Ha S; Xiong S; Chen M; Chen D; Luo G; Xiang H
    Bioorg Chem; 2023 Jan; 130():106263. PubMed ID: 36375350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
    Xing L; Huang A
    Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.